Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Opus GeneticsIRD +16.04%20 Days Sales Outstanding is 167.51 as of Jun. 2026, which is 261% above its 10-year median of 46.38. GuruFocus rates IRD with a GF Score™ of 20/100 and a GF Value™ of $0.28 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 841 Biotechnology companies, Opus Genetics ranks worse than 58.26% on this metric.
Opus Genetics's average Accounts Receivable for the
three
months ended in Jun. 2026 was $1.39 Mil. Opus Genetics's Revenue for the
three
months ended in Jun. 2026 was $0.76 Mil.
Hence, Opus Genetics's Days Sales Outstanding for the
three
months ended in Jun. 2026 was 167.51.
The historical rank and industry rank for Opus Genetics's Days Sales Outstanding or its related term are showing as below:
IRD'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 11.89 Med: 46.38 Max: 82.08
Current: 82.08
During the past 7 years, Opus Genetics's highest Days Sales Outstanding was 82.08. The lowest was 11.89. And the median was 46.38.
IRD's Days Sales Outstanding is ranked worse than 58.26% of 841
companies
in the Biotechnology industry
Industry Median: 68.98
vs IRD: 82.08
Opus Genetics's Days Sales Outstanding
increased
from Jun. 2025 (102.57) to Jun. 2026 (167.51).
Opus Genetics (NAS:IRD) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Opus Genetics Days Sales Outstanding Related Terms
Opus Genetics Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Opus Genetics's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IRD vs OBIO, CYDY, YDES: Days Sales Outstanding Comparison
For the Biotechnology subindustry, Opus Genetics's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Opus Genetics Days Sales Outstanding vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Opus Genetics's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Opus Genetics's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Days Sales Outstanding of 167.51 mean?
Opus Genetics (IRD) has a Days Sales Outstanding of 167.51 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Opus Genetics and its competitors. This is 261% above median its historical median of 46.38. Over the past decade, Opus Genetics' Days Sales Outstanding has ranged from 11.89 to 82.08. According to the industry distribution chart, Opus Genetics ranks #490 out of 841 companies in the Biotechnology industry, placing it in the top 58.3%.
Is Opus Genetics' Days Sales Outstanding too high?
Opus Genetics' current Days Sales Outstanding of 167.51 is 261% above median its 10-year median of 46.38. Over the past 10 years, this metric has ranged from a low of 11.89 to a high of 82.08. The Biotechnology industry median Days Sales Outstanding is 68.98. Opus Genetics' value of 167.51 is 142.8% above this industry median. Based on the distribution chart, Opus Genetics ranks #490 out of 841 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Opus Genetics has a GF Score™ of 20/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Opus Genetics' Days Sales Outstanding compare to OBIO and CYDY?
According to the Biotechnology industry distribution chart, Opus Genetics ranks #490 out of 841 companies for Days Sales Outstanding. This places Opus Genetics in the lower half of its industry. The industry median Days Sales Outstanding is 68.98. Opus Genetics' value of 167.51 is 142.8% above this benchmark. Historically, Opus Genetics' own Days Sales Outstanding has ranged from 11.89 to 82.08 over the past decade. While the company's 10-year median is 46.38 vs. the industry median of 68.98, Opus Genetics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 68.98, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Opus Genetics's current Days Sales Outstanding of 167.51 is 142.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Opus Genetics and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 68.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Opus Genetics's current Days Sales Outstanding is 167.51, which is 261% above median its own 10-year median of 46.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Opus Genetics stock overvalued right now?
Based on GuruFocus' analysis, Opus Genetics (IRD) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.28, compared to a current price of $4.45 — trading 1489.3% above its estimated fair value. The current Days Sales Outstanding is 167.51, which is 261% above median its 10-year median of 46.38 and 142.8% above the Biotechnology industry median of 68.98. Opus Genetics' overall GF Score™ is 20/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Opus Genetics (IRD), the current Days Sales Outstanding is 167.51 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Opus Genetics (IRD) Overvalued in 2026?
Based on GuruFocus' analysis, Opus Genetics stock appears to be overvalued.
The current stock price of $4.45 is trading 1489.3% above its estimated GF Value™ of $0.28.
GuruFocus considers Opus Genetics to be Significantly Overvalued.
Key valuation signals for IRD:
Days Sales Outstanding: 167.51 (261% above median its 10-year median of 46.38)
GF Value™: $0.28 vs. price of $4.45 (1489.3% above fair value)
Industry Position: 142.8% above the Biotechnology median (#490 of 841)
No single metric tells the full story. See the IRD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes seven adeno-associated virus (AAV)-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. The company operates in one operating segment, which is the business of developing products related to vision performance and health.
20GF Score
Get the complete analysis for IRD
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IRD has been successfully added to your 
